Lisata Therapeutics Announces 72% Workforce Reduction; CMO Exit

What Happened

• Lisata Therapeutics (LSTA) announced on August 3, 2026 that its Board approved a workforce reduction of approximately 72%, effective immediately, as part of cost-reduction initiatives while the company pursues strategic options. The company estimates about $1.2 million of charges related to severance and termination benefits to be incurred through the quarter ending September 30, 2026.
• As part of the reduction, Dr. Kristen K. Buck, M.D., Executive Vice President of R&D and Chief Medical Officer, was terminated effective August 3, 2026. Under her June 10, 2025 employment agreement, her departure is treated as a termination without Cause and — subject to her signing a release — entitles her to 12 months of base salary and target bonus and up to 12 months of COBRA premium payments.
• The Board also approved a $200,000 cash retention bonus for James Nisco, Senior Vice President, Finance and Treasury and Chief Accounting Officer; the bonus is payable within 30 days of, and conditioned on, continued employment through December 31, 2026 (with alternate payment timing if the executive is terminated without Cause and signs a release).
• Separately, on July 31, 2026 Lisata filed suit in the Delaware Court of Chancery against Kuva Labs Inc. and Kuva Acquisition Corp., alleging breach of the Merger Agreement dated March 6, 2026 and seeking damages for the benefits Lisata’s stockholders expected from the transaction.

Key Details

• Workforce cut: ~72% approved by the Board, effective August 3, 2026.
• Estimated charges: approximately $1.2 million for severance/termination benefits expected through Q3 2026.
• Executive changes: CMO Dr. Kristen Buck terminated (treated as termination without Cause); contract entitlement = 12 months base salary + target bonus and up to 12 months COBRA (subject to release).
• Retention pay: $200,000 cash bonus approved for James Nisco, payable per retention terms; lawsuit filed July 31, 2026 against Kuva Labs over alleged merger breach.

Why It Matters

• Cost and cash impact: The company expects to record about $1.2M of workforce-related charges in Q3 2026 as it reduces operating expenses. These are estimates and the filing warns actual costs could differ and additional charges could arise.
• Operational and leadership impact: The departure of the CMO and a ~72% staff reduction could materially affect R&D and day-to-day operations; Lisata says it is pursuing strategic options, which may include transactions or other changes.
• Legal and strategic risk: The lawsuit against Kuva Labs relates to a previously announced merger agreement and seeks damages for lost merger benefits—this litigation could affect the company’s strategic outcomes and potential recovery for stockholders.
• Near-term focus for investors: Watch upcoming quarterly disclosures for actual charge recognition, any updates on strategic options or transaction outcomes, and further details on how the company will manage R&D and operational continuity after the cuts.